As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in…
As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint Medicines in a deal worth $9.1 billion (£6.7 billion) in cash, with an additional $400 million on offer in…